CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update

CB-011 dose escalation data points to advances in relapsed multiple myeloma, Caribou Biosciences launches study update
Caribou Biosciences reports CB-011 data

Caribou Biosciences has released updated follow-up data from its dose escalation study of CB-011 in patients with relapsed or refractory multiple myeloma.

The latest findings will be presented during an oral session at EHA2026, highlighting the ongoing evaluation of CB-011 as a potential cell therapy solution leveraging CRISPR technology. CB-011 is part of Caribou Biosciences’ pipeline targeting hard-to-treat blood cancers and aims to address unmet needs for patients whose disease has returned or not responded to prior treatments. More details are expected at the upcoming conference and are available through Caribou Biosciences’ designated channels.

Caribou Biosciences recently participated in the Jefferies Global Healthcare Conference in New York, spotlighting its work in cell therapy and CRISPR. The company also attended the BioConnect Investor Conference, where it met with biotech investors and peers. These events form part of Caribou’s ongoing efforts to engage the healthcare and investor community.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.